Unassociated Document
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For June 12, 2008

Commission File Number: 000-51310

XTL Biopharmaceuticals Ltd.
(Translation of registrant's name into English)

711 Executive Blvd., Suite Q
Valley Cottage, New York 10989
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x  Form 40-F o  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o    No x 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A  

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
  XTL BIOPHARMACEUTICALS LTD.
 
 		  
 		  
 
Date: June 12, 2008  By:   /s/ Ron Bentsur 
 
Ron Bentsur
  Chief Executive Officer 

 

EXHIBIT INDEX

 
Exhibit
 
 
Number
Description
     
 
99.1
Press Release dated June 11, 2008.
     
 
99.2
Notice of Annual General Meeting and Notice of Extraordinary General Meeting
     
 
99.3
Form of Proxy for use at the Annual General Meeting and Extraordinary General Meeting of the Company to be held on July 17, 2008
     
  99.4 Press Release dated June 12, 2008